Connecticut's biopharmaceutical sector is characterized by innovation and research that aim to address pressing health issues. Companies involved span a wide spectrum, from established entities focusing on drug development and manufacturing to startups pushing boundaries in immunotherapy and personalized medicine. This sector is increasingly integrating advanced technologies like AI and genomic research, demonstrating a commitment to breakthrough solutions that optimize patient care. As collaboration between academia and industry grows, coupled with increased funding from investors, the future appears promising for biopharmaceutical advancements in Connecticut.

The companies in this list showcase a blend of small and mid-sized firms headquartered in Connecticut, with founding years ranging from the early 1980s to the recent 2020s. Specializations include immunotherapy, vaccine development, and precision medicine. Noteworthy examples include Simcha Therapeutics, focused on novel cancer therapies, and Protein Sciences Corporation, which targets vaccine development. This mix illustrates the robust activity and expertise found within the state's biopharmaceutical domain.

Continue reading to discover the top biopharmaceutical companies in Connecticut.

Top 25 Biopharmaceutical Companies Companies in Connecticut

1. Simcha Therapeutics

• Website: simchatx.com
• Ownership type: Venture Capital
• Headquarters: New Haven, Connecticut, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series B, $40.0M, January 2022
• Founded year: 2018
• Headcount: 1-10
• LinkedIn: simcha-therapeutics

Simcha Therapeutics is a biotechnology company based in New Haven, Connecticut, founded in 2018. The company specializes in developing innovative immunotherapies aimed at treating cancer. Their primary focus is on engineered cytokines, which are powerful proteins that regulate the immune system. One of their most advanced programs is ST-067, a novel immunotherapy that targets IL-18BP, a decoy receptor that hinders immune response in the tumor microenvironment. This approach represents a new class of interleukin-18 based therapies designed to enhance the body's immune response against cancer. Simcha Therapeutics is committed to transforming fundamental scientific discoveries into effective treatments, providing hope to cancer patients seeking advanced therapeutic options. The company has recently raised $40 million in Series B funding, reflecting strong investor interest and support for their innovative pipeline.

2. EvolveImmune Therapeutics

• Website: evolveimmune.com
• Ownership type: Venture Capital
• Headquarters: Branford, Connecticut, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $20.0M, October 2024
• Founded year: 2020
• Headcount: 11-50
• LinkedIn: evolveimmune-therapeutics

EvolveImmune Therapeutics, based in Branford, Connecticut, is a biotechnology firm that specializes in precision cancer medicines. Founded in 2020, the company is dedicated to developing innovative immunobiologics and T cell engagers aimed at enhancing anti-cancer immunity. Their research focuses on overcoming CD8 T cell exhaustion within the tumor microenvironment, which is crucial for effective cancer treatment. EvolveImmune's pipeline includes several promising candidates, such as EVOLVE-104 and EVOLVE-105, targeting various solid tumors and B cell malignancies. The company has recently secured $37 million in funding, which reflects investor confidence and supports their ongoing research and development efforts. EvolveImmune operates with a clear ambition to transform patient outcomes in cancer therapy, making it a notable player in the biopharmaceutical sector.

3. Kleo Pharmaceuticals Inc.

• Website: kleopharmaceuticals.com
• Ownership type: Corporate
• Headquarters: New Haven, Connecticut, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $20.0M, January 2021
• Founded year: 2015
• Headcount: 11-50
• LinkedIn: kleo-pharmaceuticals-inc.

Kleo Pharmaceuticals Inc. is a pharmaceutical company based in New Haven, Connecticut, established in 2015. The company is dedicated to developing innovative drug candidates aimed at addressing unmet medical needs in the fields of neuroscience, immunology, and oncology. Kleo Pharmaceuticals is actively conducting clinical trials to provide effective treatments for various conditions, including obsessive-compulsive disorder (OCD), epilepsy, and spinal muscular atrophy (SMA). With a workforce of around 24 employees, the company operates entirely within the United States. In January 2021, Kleo Pharmaceuticals secured $20 million in funding, which underscores their commitment to advancing their research and development initiatives. Their focus on creating novel therapies positions them as a relevant player in the biopharmaceutical industry.

4. Imbrium Therapeutics

• Website: imbriumthera.com
• Ownership type: Private
• Headquarters: Stamford, Connecticut, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2018
• Headcount: 11-50
• LinkedIn: imbrium-therapeutics

Imbrium Therapeutics L.P. is a clinical-stage biopharmaceutical company based in Stamford, Connecticut. Founded in 2018, Imbrium is dedicated to advancing medical science through the development of innovative therapeutics for serious medical conditions. The company has built a strong pipeline of investigational therapies, including candidates for oncology and central nervous system disorders, as well as non-opioid pain management. As a subsidiary of Purdue Pharma L.P., Imbrium aims to address significant unmet patient needs and collaborates with both commercial and academic partners to enhance their drug development efforts. Their focus on creating effective treatment options positions them as a relevant entity in the biopharmaceutical sector.

5. Normunity

• Website: normunity.com
• Ownership type: Private Equity
• Headquarters: New Haven, Connecticut, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series B, $75.0M, January 2025
• Founded year: 2020
• Headcount: 11-50
• LinkedIn: normunity

Normunity is a biotechnology firm based in New Haven, Connecticut, founded in 2020. The company is dedicated to developing precision medicines and innovative cancer immunotherapies. By leveraging proprietary platforms, Normunity aims to uncover novel mechanisms that disrupt normal immune responses in cancer, thereby creating new treatment options for patients. Their primary focus is on a new class of therapies known as immune normalizers, which aim to restore the immune system's ability to fight cancer effectively. Normunity collaborates closely with the Yale School of Medicine, enhancing their drug discovery efforts through this academic partnership. The company has also attracted significant investment, securing $75 million in Series B funding in January 2025, which underscores its potential in the biopharmaceutical landscape.

6. LAM Therapeutics

• Website: lamtherapeutics.com
• Ownership type: Private
• Headquarters: Guilford, Connecticut, United States (USA)
• Latest funding: $40.0M, February 2016
• Founded year: 2013
• Headcount: 1-10
• LinkedIn: lam-therapeutics

LAM Therapeutics, based in Guilford, Connecticut, is a biotechnology firm established in 2013. The company is dedicated to developing breakthrough therapeutics aimed at treating cancer and rare diseases. Their innovative approach leverages advanced technologies, including next-generation sequencing and artificial intelligence, to create precision medicines. LAM Therapeutics has made significant strides in clinical development, with three drug candidates—LAM-001, LAM-002, and LAM-003—currently in clinical trials. These candidates target specific conditions such as lymphangioleiomyomatosis and B-cell non-Hodgkin lymphoma. The company has successfully raised substantial funding, including a notable $40 million in 2016, which supports their ongoing research and development efforts. LAM Therapeutics serves patients and healthcare providers seeking novel treatment options, reflecting their commitment to addressing unmet medical needs.

7. BioXcel, LLC

• Website: bioxcel.com
• Ownership type: Private
• Headquarters: Guilford, Connecticut, United States (USA)
• Employee distribution: India 90%, United States (USA) 10%
• Founded year: 2005
• Headcount: 51-200
• LinkedIn: bioxcel-corporation

BioXcel, LLC, based in Guilford, Connecticut, is a biopharmaceutical company founded in 2005. The company specializes in developing transformative medicines by leveraging advanced artificial intelligence technology. BioXcel is particularly focused on addressing significant unmet medical needs in the fields of neuroscience and immuno-oncology. Their flagship product, IGALMI™ (dexmedetomidine), is an FDA-approved sublingual film designed for the acute treatment of agitation associated with schizophrenia and bipolar disorders. This product highlights BioXcel's ability to navigate the complexities of drug development efficiently. The company operates through its AI platform, EvolverAI, which enhances the drug discovery process by optimizing research and development timelines and reducing costs. BioXcel also has a family of companies, including BioXcel Therapeutics, Inc. and InveniAI® LLC, which further extend their capabilities in drug development and innovation.

8. Cybrexa Therapeutics

• Website: cybrexa.com
• Ownership type: Venture Capital
• Headquarters: New Haven, Connecticut, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series B, $25.0M, March 2021
• Founded year: 2017
• Headcount: 11-50
• LinkedIn: cybrexa-therapeutics

Cybrexa Therapeutics is a biotechnology firm based in New Haven, Connecticut, founded in 2017. The company specializes in developing novel cancer therapeutics, particularly through its proprietary alphalex technology platform. This platform focuses on creating peptide-drug conjugates that enhance the delivery of anti-cancer agents directly to tumor cells, thereby improving treatment efficacy while minimizing side effects. Cybrexa's primary product in development, CBX-12, is currently undergoing Phase 2 clinical trials for treating platinum-resistant ovarian cancer. The company has also reported positive results from earlier trials, showcasing its potential across multiple solid tumor types. With a dedicated team of physician-scientists and experienced management, Cybrexa is positioned to make significant contributions to oncology. The company has attracted $25 million in funding as of March 2021, which underscores investor confidence in its innovative approach and pipeline.

9. Vanessa Research, Inc.

• Website: vanessaresearch.com
• Ownership type: Private
• Headquarters: Hamden, Connecticut, United States (USA)
• Founded year: 2014
• Headcount: 51-200
• LinkedIn: vri

Vanessa Research, Inc., now operating under the name Vanessa Biotech, is a private biomedical company based in Hamden, Connecticut. Founded in 2014, the company is dedicated to developing innovative healthcare solutions specifically targeting rare diseases. Their primary focus is on creating pharmaceuticals like Shylicine™, which is designed to treat microvillus inclusion disease (MVID), a rare genetic disorder that causes severe diarrhea in infants. Vanessa Biotech is involved in both research and development as well as pharmaceutical manufacturing, aiming to improve patient access to essential treatments. The company has also expanded its operations internationally, with offices in Hungary, Spain, and Germany, reflecting its ambition to make a global impact in healthcare. Their commitment to addressing overlooked healthcare markets is evident in their ongoing research and the development of additional products aimed at gastrointestinal diseases and other medical needs.

10. Protein Sciences Corporation

• Website: proteinsciences.com
• Ownership type: Corporate
• Headquarters: Meriden, Connecticut, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $650.0M, July 2017
• Founded year: 1983
• Headcount: 51-200
• LinkedIn: protein-sciences-corporation

Protein Sciences Corporation, based in Meriden, Connecticut, is a corporate entity founded in 1983. The company specializes in the development and distribution of vaccines, with a particular emphasis on influenza prevention. Their primary products include Fluzone and Flublok, which are designed to protect against influenza A and B viruses. Flublok is notable for being the first recombinant influenza vaccine, utilizing advanced technology to enhance efficacy and safety. The company operates entirely within the United States and has a workforce of approximately 51 to 200 employees. In 2017, Protein Sciences Corporation secured significant funding amounting to $650 million, underscoring investor confidence in their innovative approach to vaccine development. Their focus on providing essential immunization solutions positions them as a key player in the healthcare sector, particularly in the fight against seasonal influenza.

11. Bexorg, Inc.

• Website: bexorg.com
• Ownership type: Private
• Headquarters: New Haven, Connecticut, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2021
• Headcount: 11-50
• LinkedIn: bexorg-inc

Bexorg, Inc. is a biotechnology firm based in New Haven, Connecticut, founded in 2021. The company specializes in neuroscience research, aiming to revolutionize the understanding and treatment of brain diseases. Bexorg has developed a proprietary whole-brain perfusion model, which allows researchers to manipulate and record cellular activity in intact brains for extended periods. This innovative platform is designed to overcome the limitations of traditional cell cultures and organoids, providing a more accurate representation of brain function. Bexorg's technology is geared towards researchers and pharmaceutical companies, facilitating the exploration of brain connectivity, circuit function, and the effects of drugs on the brain. The company has garnered attention for its scientific contributions, with over 800 brain runs conducted during its research and development phase, and has been featured in several high-profile publications. Bexorg's mission is to create a world free of brain disease, positioning it as a significant player in the biopharmaceutical industry.

12. InveniAI

• Website: inveniai.com
• Ownership type: Private
• Headquarters: Guilford, Connecticut, United States (USA)
• Latest funding: $3.1M, June 2024
• Founded year: 2017
• Headcount: 11-50
• LinkedIn: inveniai

InveniAI, founded in 2017 and based in Guilford, Connecticut, is a private company that specializes in leveraging artificial intelligence and machine learning to transform drug discovery and development. Their flagship platform, AlphaMeld®, integrates complex scientific, medical, and biological data to assist biopharmaceutical companies in identifying and developing therapies for diseases with unmet medical needs. InveniAI has formed over 150 collaborations with various stakeholders in the biopharma industry, showcasing its commitment to enhancing the drug development process. The company aims to amplify human productivity and improve clinical success rates by providing innovative AI-powered solutions. InveniAI has also secured funding, with a reported amount of $3.1 million in June 2024, which supports its ongoing efforts to advance healthcare innovation.

13. NGT BioPharma Consultants

• Website: ngtbiopharmaconsultants.com
• Ownership type: Private
• Headquarters: East Lyme, Connecticut, United States (USA)
• Employee distribution: United States (USA) 58%, United Kingdom (UK) 11%, Canada 11%, Other 21%
• Founded year: 2018
• Headcount: 51-200
• LinkedIn: ngtbiopharmaconsultants

NGT BioPharma Consultants, founded in 2018 and based in East Lyme, Connecticut, is a private consulting firm dedicated to drug development and advanced technologies. With a team of experienced professionals, they provide a comprehensive suite of services that includes regulatory strategy, quality compliance, and pediatric drug development consulting. Their clientele spans various sectors, including pharmaceutical and biotech companies, academic institutions, and healthcare investors, all seeking expert guidance to navigate the intricate processes of drug development. NGT BioPharma Consultants emphasizes customized solutions tailored to the specific needs of their clients, ensuring that they can effectively support drug candidates from late discovery through commercialization. Their Pediatric Center of Excellence further showcases their commitment to addressing the unique challenges associated with developing safe and effective medications for children. Although they have not reported any funding, their established presence and expertise in the biopharmaceutical industry underscore their role as a valuable consulting partner.

14. Virscio

• Website: virscio.com
• Ownership type: Venture Capital
• Headquarters: New Haven, Connecticut, United States (USA)
• Employee distribution: Saint Kitts and Nevis 51%, United States (USA) 49%
• Latest funding: January 2008
• Founded year: 2002
• Headcount: 51-200
• LinkedIn: rxgen

Virscio is a biomedical research company based in New Haven, Connecticut, founded in 2002. The company specializes in preclinical services, offering advanced preclinical models and research services tailored to the needs of biotechnology and pharmaceutical firms. Virscio's primary goal is to accelerate therapeutic innovation and improve research and development efficiency by providing high-quality, predictive preclinical data. They focus on using nonhuman primate models to enhance the accuracy of clinical outcome predictions, which is critical for reducing the time, cost, and risk associated with bringing new therapies to market. With a commitment to ethical standards and animal welfare, Virscio operates facilities in both the United States and St. Kitts, where they maintain a biologically clean population of African green monkeys for research purposes. Their expertise spans various therapeutic areas, including ophthalmology, central nervous system disorders, and gene therapy, making them a significant player in the biopharmaceutical landscape.

15. Torigen, Inc.

• Website: torigen.com
• Ownership type: Private Equity
• Headquarters: Farmington, Connecticut, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series A, $13.0M, May 2022
• Founded year: 2013
• Headcount: 11-50
• LinkedIn: torigen-pharmaceuticals

Torigen, Inc., founded in 2013 and based in Farmington, Connecticut, is a biotechnology firm dedicated to improving cancer treatment for companion animals. The company specializes in personalized cancer immunotherapy, utilizing a unique vaccine derived from the tumor cells of pets. This innovative approach allows for tailored treatment options that harness the pet's immune system to target and attack cancer cells. Torigen primarily serves veterinarians and pet owners, providing educational resources and support to veterinary clinics to facilitate the use of their treatments. The company has made strides in the veterinary oncology field, evidenced by their recent Series A funding of $13 million in May 2022, which underscores their growth potential and commitment to advancing veterinary cancer care.

16. TriRx Pharmaceutical Services, LLC

• Website: trirx.com
• Ownership type: Private
• Headquarters: Norwalk, Connecticut, United States (USA)
• Employee distribution: United States (USA) 59%, United Kingdom (UK) 23%, France 18%
• Founded year: 2019
• Headcount: 201-500
• LinkedIn: trirx

TriRx Pharmaceutical Services, LLC, based in Norwalk, Connecticut, is a contract development and manufacturing organization (CDMO) that specializes in pharmaceutical manufacturing. Founded in 2019, TriRx offers a wide range of services tailored to the needs of pharmaceutical companies, including the production of oral solid doses, semi-solids, liquids, and biologics. With facilities strategically located in Huntsville, Alabama; Shawnee, Kansas; Segré, France; and Speke, Liverpool, UK, TriRx is well-equipped to support the commercialization of drug products across global markets. The company prides itself on its commitment to quality, regulatory compliance, and customer service, ensuring that clients receive not only manufacturing services but also a partnership that prioritizes their product's success. TriRx operates under stringent regulatory approvals, including those from the FDA and EMA, which underscores their capability to meet high industry standards. Their focus on innovation and operational excellence positions them as a valuable ally in the biopharmaceutical industry.

17. Propria LLC

• Website: propriabio.com
• Ownership type: Venture Capital
• Headquarters: Branford, Connecticut, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Seed, $121,000, December 2019
• Founded year: 2018
• Headcount: 1-10
• LinkedIn: propria-llc

Propria LLC, founded in 2018 and based in Branford, Connecticut, is a biotechnology firm focused on advancing cardiac research through innovative technologies. The company specializes in cardiac contractility testing and engineered heart tissues, offering services that include contractile profiling and disease modeling. Propria collaborates with pharmaceutical and biotech companies to assess the efficacy of new therapeutics, providing critical insights into heart function. Their proprietary MyoPod™ platform produces human engineered heart tissues that closely mimic adult human myocardium, allowing for more accurate predictions of human physiology. Propria has received seed funding, which supports its ongoing research and development efforts in the field of cardiac physiology.

18. HealthCare Royalty

• Website: hcrx.com
• Ownership type: Private
• Headquarters: Stamford, Connecticut, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2007
• Headcount: 11-50
• LinkedIn: healthcare-royalty-partners

HealthCare Royalty, founded in 2007 and based in Stamford, Connecticut, operates as a financial services firm with a specialized focus on the biopharmaceutical sector. The company provides innovative capital solutions through royalty monetization and corporate financing, helping biopharmaceutical companies, research institutions, and inventors access necessary funding while preserving equity. With a portfolio that boasts over $5 billion invested in more than 85 biopharma products, HealthCare Royalty plays a pivotal role in facilitating the development and commercialization of important pharmaceutical products. Their approach is characterized by a commitment to long-term partnerships, tailoring financial solutions to meet the unique needs of their clients. This strategic involvement not only supports the growth of their partners but also contributes to the overall advancement of healthcare innovation.

19. Clinical Research Consulting LLC

• Website: clinicalrc.com
• Ownership type: Private
• Headquarters: Milford, Connecticut, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 1990
• Headcount: 11-50
• LinkedIn: clinical-research-consulting-llc

Clinical Research Consulting LLC, based in Milford, Connecticut, is a clinical research organization established in 1990. The company specializes in conducting high-quality clinical trials across multiple therapeutic areas, providing essential services to pharmaceutical sponsors and CROs. Their expertise lies in patient recruitment and ensuring compliance with regulatory standards, which are critical components in the clinical trial process. With facilities in Connecticut and New Jersey, Clinical Research Consulting is equipped with modern technology and a skilled team, including physicians and study coordinators, to support the execution of Phase II, III, and IV clinical trials. They have built strong relationships with numerous sponsors and CROs, contributing to their reputation as a reliable site for clinical research. Their commitment to quality and efficiency is reflected in their proactive approach to study execution and patient engagement.

20. QCDx

• Website: qcd-x.com
• Ownership type: Private
• Headquarters: Farmington, Connecticut, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $1.7M, May 2025
• Founded year: 2017
• Headcount: 1-10
• LinkedIn: qcdx-llc

QCDx, founded in 2017 and based in Farmington, Connecticut, is a medical diagnostics company dedicated to cancer treatment optimization. The firm specializes in advanced technologies that enable the detection and profiling of rare circulating tumor cells (CTCs) in blood samples. Their flagship products, the RareScope™ system and MultiFluor™ probes, provide oncologists with real-time insights that can significantly enhance treatment strategies. QCDx primarily serves healthcare providers and research institutions, focusing on improving patient outcomes through precision cancer diagnostics. The company has also engaged in clinical trials, such as the CLINBREAC study, to assess the clinical utility of their technologies. Recently, QCDx secured $1.7 million in funding, indicating investor confidence in their innovative approach to cancer diagnostics and treatment optimization.

21. AVS Bio

• Website: avsbio.com
• Ownership type: Private Equity
• Headquarters: Norwich, Connecticut, United States (USA)
• Employee distribution: United States (USA) 98%, Spain 2%
• Latest funding: January 2023
• Founded year: 1961
• Headcount: 201-500
• LinkedIn: avsbio

AVS Bio, based in Norwich, Connecticut, is a biotechnology company that has been operational since 1961. Originally founded as SPAFAS, the company specializes in the production of Specific Pathogen Free (SPF) eggs, which are crucial for vaccine and therapeutic development. They provide a range of laboratory products and services that support biologic manufacturing, emphasizing quality, biosecurity, and scientific innovation. AVS Bio has produced over one billion SPF eggs since its inception and operates more than 40 production houses across the United States. The company has a strong commitment to the humane treatment of animals and sustainable practices in its operations. After operating as a subsidiary of Charles River Laboratories for 30 years, AVS Bio became an independent entity in 2022, allowing for a renewed focus on investment and growth in the immunology sector. Their products are utilized in both human and animal health markets, making them a significant player in the biopharmaceutical industry.

22. XingImaging, LLC

• Website: xingimaging.com
• Ownership type: Corporate
• Headquarters: Madison, Connecticut, United States (USA)
• Employee distribution: United States (USA) 91%, United Kingdom (UK) 9%
• Latest funding: $30.2M, December 2022
• Founded year: 2018
• Headcount: 11-50
• LinkedIn: xingimaging-llc

XingImaging, LLC, founded in 2018 and based in Madison, Connecticut, is a clinical research company that specializes in neuroimaging services. With a team of approximately 33 employees, the company focuses on providing comprehensive support for radiopharmaceutical imaging trials. Their expertise lies in radioligand development and clinical trial management, particularly for neurodegenerative disorders. XingImaging's services span the pre-clinical and clinical phases, including the design and implementation of clinical trials from Phase 1 to Phase 4. They are known for their commitment to quality and compliance with regulatory standards, ensuring that their research participants receive compassionate and confidential care. In December 2022, the company secured $30.2 million in funding, which underscores their growth potential and relevance in the biopharmaceutical sector. Their collaboration with MITRO Biotech Co., Ltd. further enhances their capabilities in drug development and imaging solutions, solidifying their position in the industry.

23. Early Access Care, LLC

• Website: earlyaccesscare.com
• Ownership type: Private
• Headquarters: Madison, Connecticut, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2016
• Headcount: 51-200
• LinkedIn: early-access-care

Early Access Care, LLC, founded in 2016 and based in Madison, Connecticut, is a consulting firm dedicated to improving patient access to investigational medicinal products. The company assists pharmaceutical companies, physicians, and patients in navigating the complex regulatory pathways associated with expanded access and compassionate use programs. Their services include managing access programs, developing policies, and collecting real-world data to ensure that patients with serious medical conditions can obtain necessary therapies. With a team boasting over 50 years of experience in drug development and 25 years in compassionate use, Early Access Care is well-equipped to guide biopharma companies through the intricacies of FDA regulations and international access protocols. Their proprietary Early Access System™ streamlines the management of access requests, enhancing the efficiency of the process for both patients and healthcare providers.

24. International HealthCare, LLC

• Website: ihcresearch.com
• Ownership type: Private
• Headquarters: Norwalk, Connecticut, United States (USA)
• Employee distribution: United States (USA) 85%, Italy 15%
• Founded year: 2002
• Headcount: 11-50
• LinkedIn: international-healthcare-llc

International HealthCare, LLC (IHC) is a private contract research organization based in Norwalk, Connecticut, founded in 2002. The company specializes in providing clinical research services, regulatory strategy, and product development support to the pharmaceutical, biotechnology, and medical device industries. IHC assists clients in designing, monitoring, and managing all phases of clinical trials, ensuring adherence to regulatory standards and facilitating successful product approvals. With a team of experienced professionals, IHC has been instrumental in the clinical program management of various drugs and medical devices currently available in the market. Their services include project management, site management, medical writing, regulatory affairs, safety and ethics review, and data management. IHC's commitment to utilizing advanced technology enhances data integrity and accelerates the clinical research process, making them a valuable partner for companies seeking to navigate the complexities of clinical trials and regulatory compliance.

25. Prometheus Research, an IQVIA business

• Website: prometheusresearch.com
• Ownership type: Private
• Headquarters: New Haven, Connecticut, United States (USA)
• Latest funding: Other (Debt), February 2017
• Founded year: 1999
• Headcount: 51-200
• LinkedIn: prometheus-research-llc

Prometheus Research, an IQVIA business, is a healthcare analytics provider based in New Haven, Connecticut. Founded in 1999, the company specializes in offering a range of services that cater primarily to the pharmaceutical and biotech sectors. Their expertise lies in research and development, real-world evidence generation, and commercialization solutions. Prometheus Research leverages extensive data assets to provide insights that help clients navigate the complexities of clinical development and regulatory compliance. By focusing on data-driven strategies, they assist companies in making informed decisions that ultimately aim to improve patient outcomes. As part of IQVIA, they benefit from a global network and advanced technological capabilities, enhancing their ability to deliver impactful solutions to their clients.

Biopharmaceutical Companies Insights: Key Companies in Connecticut

Want to Find More Biopharmaceutical Companies Companies?

With Inven you'll also get to know the company's:

• Detailed Ownership: Who owns the company? Is it a public or private company? What is the ownership structure?
• Contact data: Who are the founders and CEO's? What are their emails and phone numbers?
• Financials: How do these companies perform financially? What are their revenues and profit margins?

...and a lot more!